StockNews.AI
XERS
StockNews.AI
12 days

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

1. Xeris reported a 50% year-over-year revenue increase to $72 million. 2. Company updates its fiscal 2025 guidance, indicating strong performance.

Earnings
+21.6%Current Return
VS
+0.73%S&P 500
$5.4908/07 07:14 AM EDTEvent Start
$6.675608/08 02:10 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

The strong revenue growth and positive guidance suggest robust demand, historically linked to stock price increases.

How important is it?

Significant revenue growth may attract investor interest, directly impacting stock performance.

Why Short Term?

The quarterly results will likely influence stock performance quickly, as investors react to financials.

Related Companies

XERSAMGNSNY
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. “Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three.

Related News